Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1101-1120 of 1,743 trials

Breast Reconstruction Surgery: Opioid-Free vs. Opioid-Based Anesthesia

We are studying the effects of opioid-free anesthesia compared to traditional opioid-based anesthesia in patients undergoing breast reconstruction surgery. This research aims to find safer pain management options.

Anesthesia during Breast Reconstruction Surgery>2 yearsConfirmation phase (III)OncologyOtolaryngology

Ventilator-Associated Pneumonia: Antimicrobial Stewardship Study

We are exploring a new method for managing antibiotics in patients with Ventilator-Associated Pneumonia in intensive care. This study aims to see if daily assessments can improve survival and reduce complications.

Ventilator Associated PneumoniaIntensive Care>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Acute Pyelonephritis: Short vs. Long Antibiotic Treatment

We are studying whether a 7-day antibiotic treatment is as effective as a 14-day treatment for kidney transplant recipients with acute pyelonephritis. This research aims to improve treatment options and patient safety.

Kidney Infection (Pyelonephritis)Kidney Transplant Recipients>2 yearsMonitoring phase (IV)Standard MedicinesInfectious DiseasesNephrologyUrology

Lupus Nephritis: KYV-101 CAR T-Cell Therapy

We are testing a new immune cell therapy for individuals with refractory lupus nephritis. The goal is to see if it can improve kidney function in patients who have not responded to other treatments.

Lupus Nephritis>2 yearsSafety phase (I)Efficacy phase (II)NephrologyRheumatology

Transfusion-Dependent β-Thalassemia: CTX001 Treatment

We are studying a new cell therapy for children with transfusion-dependent β-thalassemia to see if it can improve their condition and reduce the need for blood transfusions. The trial will also assess the safety of this treatment.

Transfusion-Dependent Thalassemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Portosinusoidal Vascular Disorder: Edoxaban Study

We are studying the safety of edoxaban in patients with Portosinusoidal Vascular Disorder. The trial also explores its potential to prevent blood clots and improve quality of life.

Porto-Sinusoidal Vascular Disorder>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteCardiology

Skin Cancer Treatment: The BLESS Trial

We are investigating whether reducing the dose of bleomycin in electrochemotherapy can still effectively treat skin cancers. This study aims to see if patients can benefit from less medication while achieving similar tumor response.

Skin Cancer>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesDermatologyOncology

Behçet’s Disease Uveitis: Adalimumab vs. Tocilizumab

We are comparing two biologic treatments for severe uveitis in Behçet’s disease to see which one may better improve vision and reduce inflammation. This study will also evaluate the safety of both medications.

Severe Uveitis of Behçet’s Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOphthalmologyRheumatology

BRAF Mutated Melanoma: Encorafenib and Binimetinib with Cemiplimab and Fianlimab

We are studying a combination of treatments for patients with BRAF mutated melanoma and brain metastases. The goal is to see if this approach can help control the disease and improve survival.

Melanoma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyOncology

Colorectal Cancer: PIPAC Treatment Study

We are testing a new chemotherapy method to prevent cancer spread in patients who have had surgery for high-risk colorectal cancer. This study will help us understand its effectiveness and impact on patients' quality of life.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Parkinson's Disease: BIIB122 Treatment Study

We are studying the safety and effects of BIIB122 in people with LRRK2-associated Parkinson's disease. This trial aims to understand how well the treatment engages important biological pathways.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurology

High-Grade Glioma: New Imaging Technique

We are testing a new method using special dyes to help surgeons better identify and remove tumors in patients with high-grade glioma. This study aims to refine how we assess tumor margins during surgery.

Glioblastoma>2 yearsSafety phase (I)NeurologyOncology

Brigatinib for Pediatric and Young Adult ALK+ Cancer

We are studying the safety and effectiveness of brigatinib in children and young adults with ALK+ Anaplastic Large Cell Lymphoma and other solid tumors. This trial aims to find the best dose and understand how the drug works in these patients.

Anaplastic Large Cell Lymphoma (ALCL)Inflammatory Myofibroblastic Tumors (IMT)Other Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncologyPediatrics

Cortisone Treatment for Children with Facial Nerve Palsy

We are studying whether cortisone can help children with acute facial nerve paralysis recover better than a placebo. The trial will also look at safety and how the condition affects daily life.

Facial Nerve Palsy (Bell's Palsy)>2 yearsMonitoring phase (IV)Standard MedicinesNeurologyPediatrics

NK Cell Infusion for Sarcoma in Young Patients

We are testing a new immunotherapy using activated NK cells for children, adolescents, and young adults with refractory sarcomas. The goal is to evaluate its safety and effects after chemotherapy or radiotherapy.

Sarcomas>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Recurrent Meningioma: [177Lu]Lu-DOTATATE Treatment Study

We are investigating whether [177Lu]Lu-DOTATATE can effectively treat recurrent meningioma compared to standard care. The study will also look at safety and quality of life for participants.

Meningioma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesNeurologyOncology

Kidney Transplantation: Donor Modified Immune Cells

We are studying whether using specially modified immune cells can help patients tolerate their new kidney better than standard treatments. The trial also looks at the safety of this new approach in preventing infections and other complications.

Kidney Transplant>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Multiple Sclerosis: Treatment Withdrawal Study for Older Adults

We are investigating whether stopping disease-modifying therapies is safe for people aged 55 and over with inactive relapsing-remitting multiple sclerosis. The study will help us understand its effects on relapse rates, disability, and quality of life.

Multiple Sclerosis>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Cataract Surgery: Clobetasol vs. Prednisolone in Young Children

We are studying a new eye treatment for inflammation after cataract surgery in children aged 0 to 3 years. The goal is to see if it is safer and more effective than the standard treatment.

Eye Inflammation and Pain>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesOphthalmologyPediatrics

M9466 for Advanced Solid Tumors

We are investigating the effects of M9466, both alone and with other treatments, in patients with advanced solid tumors. This study aims to find out how well it works in this patient group.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology